Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z. Usmani, Amrita Krishnan, Lixia Pei et al.|The Lancet|2021Cited by 321
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myelomaSuzette Girgis, Jenna D. Goldberg, Shun Xin Wang Lin et al.|Blood Advances|2022Cited by 52
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).Alfred L. Garfall, María‐Victoria Mateos, Hareth Nahi et al.|Journal of Clinical Oncology|2020Cited by 42
Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple MyelomaSuzette Girgis, Yusri Elsayed, Shun Xin Wang Lin et al.|Targeted Oncology|2022Cited by 21
Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma PatientsSuzette Girgis, Amarnath Sharma, Shun Xin Wang Lin et al.|Blood|2020Cited by 2